RU2018131237A - Способы лечения атопического дерматита с помощью антагониста il-4r - Google Patents
Способы лечения атопического дерматита с помощью антагониста il-4r Download PDFInfo
- Publication number
- RU2018131237A RU2018131237A RU2018131237A RU2018131237A RU2018131237A RU 2018131237 A RU2018131237 A RU 2018131237A RU 2018131237 A RU2018131237 A RU 2018131237A RU 2018131237 A RU2018131237 A RU 2018131237A RU 2018131237 A RU2018131237 A RU 2018131237A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- patient
- dose
- antibody
- administered
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 8
- 206010012438 Dermatitis atopic Diseases 0.000 title claims 3
- 201000008937 atopic dermatitis Diseases 0.000 title claims 3
- 239000005557 antagonist Substances 0.000 title 1
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 239000012634 fragment Substances 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 239000003246 corticosteroid Substances 0.000 claims 6
- 229960001334 corticosteroids Drugs 0.000 claims 6
- 230000000699 topical effect Effects 0.000 claims 6
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 5
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 5
- 208000003251 Pruritus Diseases 0.000 claims 5
- 208000037851 severe atopic dermatitis Diseases 0.000 claims 4
- 230000007803 itching Effects 0.000 claims 3
- 229940122739 Calcineurin inhibitor Drugs 0.000 claims 2
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 claims 2
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 claims 2
- 229940125379 topical corticosteroid Drugs 0.000 claims 2
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 102000054663 human IL4R Human genes 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/202—Dermatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
Claims (15)
1. Фармацевтическая композиция, содержащая терапевтически эффективное количество антитела к рецептору интерлейкина-4 (IL-4R) человека или его антигенсвязывающего фрагмента для лечения, уменьшения выраженности, ослабления, облегчения или предупреждения кожного зуда у пациента, где пациент страдает от умеренно тяжелого до тяжелого атопического дерматита (АД).
2. Фармацевтическая композиция по п. 1, где пациент, страдающий от умеренно тяжелого до тяжелого атопического дерматита, демонстрирует балл по числовой шкале оценки интенсивности кожного зуда (NRS) ≥5 и/или балл cогласно 5-D Pruritus ≥18.
3. Фармацевтическая композиция по п. 1 или 2, где пациент, страдающий от умеренно тяжелого до тяжелого атопического дерматита, является устойчивым к лечению топическим кортикостероидом (ТКС) или ингибитором кальциневрина.
4. Фармацевтическая композиция по п. 3, где устойчивость включает ухудшение соблюдения пациентом режима и схемы лечения и/или токсичность и побочные эффекты, и/или неэффективность топических кортикостероидов или ингибитора кальциневрина, вводимых для лечения, снижения, ослабления или предупреждения кожного зуда.
5. Фармацевтическая композиция по любому из пп. 1-4, где фармацевтическая композиция содержит от около 50 до около 600 мг антитела к IL-4R человека или его антигенсвязывающего фрагмента.
6. Фармацевтическая композиция по любому из пп. 1-4, где фармацевтическая композиция содержит около 300 мг антитела к IL-4R человека или его антигенсвязывающего фрагмента.
7. Фармацевтическая композиция по любому из пп. 1-6, где антитело или его антигенсвязывающий фрагмент содержат определяющие комплементарность участки (CDR) тяжелой и легкой цепей в паре аминокислотных последовательностей вариабельной области тяжелой цепи/вариабельной области легкой цепи (HCVR/LCVR), содержащей SEQ ID NO: 162/164.
8. Фармацевтическая композиция по п. 7, где антитело или его антигенсвязывающий фрагмент содержат три CDR тяжелой цепи (HCDR), содержащие SEQ ID NO: 148, 150 и 152, соответственно; и три последовательности CDR легкой цепи (LCDR), содержащие SEQ ID NO: 156, 158 и 160, соответственно.
9. Способ лечения, уменьшения выраженности, ослабления, облегчения или предупреждения кожного зуда у пациента, где пациент страдает от умеренно тяжелого до тяжелого атопического дерматита (АД), включающий введение фармацевтической композиции по любому из пп. 1-8 указанному пациенту.
10. Способ по п. 9, где фармацевтическую композицию вводят в первоначальной дозе пациенту и вводят одну или более последующих доз пациенту.
11. Способ по п. 10, где первоначальная доза содержит около 300 или около 600 мг антитела к IL-4R человека или его антигенсвязывающего фрагмента, и где каждая последующая доза содержит от около 75 до около 300 мг антитела к IL-4R человека или его антигенсвязывающего фрагмента.
12. Способ по п. 10 и 11, где каждую дозу вводят через 1 неделю или 2 недели после непосредственно предшествующей дозы.
13. Способ по любому из пп. 9-12, где топические кортикостероиды вводят пациенту одновременно с фармацевтической композицией.
14. Способ по п. 13, где топические кортикостероиды вводят одновременно с фармацевтической композицией пациенту во время начального периода, и где дозу топических кортикостероидов постепенно уменьшают во время последующего периода, когда дозу топических кортикостероидов постепенно уменьшают, тогда как антитело к IL-4R человека или его антигенсвязывающий фрагмент вводят в тех же дозах, как во время начального периода.
15. Способ по п. 14, где доза топических кортикостероидов снижается на 10%, 20%, 30%, 40%, 50% или более во время последующего периода по сравнению с дозой в начальный период.
Applications Claiming Priority (18)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261697972P | 2012-09-07 | 2012-09-07 | |
| US61/697,972 | 2012-09-07 | ||
| US201261738715P | 2012-12-18 | 2012-12-18 | |
| US61/738,715 | 2012-12-18 | ||
| US201361748588P | 2013-01-03 | 2013-01-03 | |
| US61/748,588 | 2013-01-03 | ||
| US201361764624P | 2013-02-14 | 2013-02-14 | |
| US61/764,624 | 2013-02-14 | ||
| US201361768229P | 2013-02-22 | 2013-02-22 | |
| US61/768,229 | 2013-02-22 | ||
| US201361770091P | 2013-02-27 | 2013-02-27 | |
| US61/770,091 | 2013-02-27 | ||
| US201361782420P | 2013-03-14 | 2013-03-14 | |
| US61/782,420 | 2013-03-14 | ||
| US201361816191P | 2013-04-26 | 2013-04-26 | |
| US61/816,191 | 2013-04-26 | ||
| FR1356759 | 2013-07-10 | ||
| FR1356759 | 2013-07-10 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015108073A Division RU2666630C2 (ru) | 2012-09-07 | 2013-09-04 | Способы лечения атопического дерматита с помощью антагониста il-4r |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018131237A true RU2018131237A (ru) | 2018-10-04 |
| RU2018131237A3 RU2018131237A3 (ru) | 2019-03-14 |
| RU2698907C2 RU2698907C2 (ru) | 2019-09-02 |
Family
ID=50233497
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015108073A RU2666630C2 (ru) | 2012-09-07 | 2013-09-04 | Способы лечения атопического дерматита с помощью антагониста il-4r |
| RU2018131237A RU2698907C2 (ru) | 2012-09-07 | 2013-09-04 | Способы лечения атопического дерматита с помощью антагониста il-4r |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015108073A RU2666630C2 (ru) | 2012-09-07 | 2013-09-04 | Способы лечения атопического дерматита с помощью антагониста il-4r |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US20140072583A1 (ru) |
| EP (4) | EP3354663A1 (ru) |
| JP (3) | JP6353838B2 (ru) |
| KR (3) | KR102122708B1 (ru) |
| CN (3) | CN118286430A (ru) |
| AR (1) | AR092475A1 (ru) |
| AU (4) | AU2013312868B2 (ru) |
| BR (1) | BR112015005048A8 (ru) |
| CA (1) | CA2883936C (ru) |
| CY (1) | CY1121906T1 (ru) |
| DK (1) | DK2892927T3 (ru) |
| ES (2) | ES2675779T3 (ru) |
| HK (1) | HK1209132A1 (ru) |
| HR (1) | HRP20181227T1 (ru) |
| HU (2) | HUE066738T2 (ru) |
| IL (1) | IL237328B (ru) |
| LT (1) | LT2892927T (ru) |
| MX (1) | MX363193B (ru) |
| NZ (3) | NZ748451A (ru) |
| PL (1) | PL2892927T3 (ru) |
| PT (1) | PT3889181T (ru) |
| RS (1) | RS57520B1 (ru) |
| RU (2) | RU2666630C2 (ru) |
| SG (2) | SG11201501011WA (ru) |
| SI (1) | SI2892927T1 (ru) |
| TR (1) | TR201808181T4 (ru) |
| TW (4) | TWI699212B (ru) |
| UY (1) | UY35013A (ru) |
| WO (1) | WO2014039461A1 (ru) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX344294B (es) | 2010-10-06 | 2016-12-13 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r). |
| ES2900342T3 (es) | 2012-08-21 | 2022-03-16 | Sanofi Biotechnology | Métodos para tratar o prevenir el asma administrando un antagonista de IL-4R |
| PL2892927T3 (pl) | 2012-09-07 | 2018-11-30 | Regeneron Pharmaceuticals, Inc. | Sposoby leczenia atopowego zapalenia skóry przez podawanie antagonisty IL-4R |
| TWI633891B (zh) * | 2013-06-04 | 2018-09-01 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法 |
| TWI709411B (zh) | 2013-06-21 | 2020-11-11 | 法商賽諾菲生物技術公司 | Il-4r拮抗劑用於製備治療鼻息肉症的醫藥品之用途 |
| TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| IL315136A (en) | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by adding an IL-4R antagonist |
| CA2939506C (en) * | 2014-02-28 | 2022-08-23 | Regeneron Pharmaceuticals, Inc. | Methods for treating skin infection by administering an il-4r antagonist |
| US10584344B2 (en) * | 2014-06-17 | 2020-03-10 | Crown Laboratories, Inc. | Genetically modified bacteria and methods for genetic modification of bacteria |
| TWI745962B (zh) | 2014-06-27 | 2021-11-11 | 法商賽諾菲公司 | 測定投予至人類個體之包括雙-v-區類抗體蛋白或其片段的劑量是否在人類個體中與il-4或il-13特異性結合之方法 |
| KR20170081262A (ko) | 2014-11-14 | 2017-07-11 | 사노피 바이오테크놀로지 | Ｉｌ-4ｒ 길항제의 투여에 의한, 비용종을 동반한 만성 부비동염의 치료 방법 |
| US10858437B2 (en) | 2015-04-02 | 2020-12-08 | Intervet, Inc. | Antibodies to canine interleukin-4 receptor alpha |
| TWI826814B (zh) | 2015-04-14 | 2023-12-21 | 日商中外製藥股份有限公司 | 含有il-31拮抗劑作為有效成分之異位性皮膚炎的預防用及/或治療用醫藥組合物 |
| PL3416685T3 (pl) | 2016-02-19 | 2024-08-26 | Regeneron Pharmaceuticals, Inc. | Sposoby wzmocnienia skuteczności szczepionki przez podawanie antagonisty il-4r |
| CN113372446A (zh) | 2016-06-08 | 2021-09-10 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| WO2018045130A1 (en) * | 2016-09-01 | 2018-03-08 | Regeneron Pharmaceuticals, Inc. | Methods for preventing or treating allergy by administering an il-4r antagonist |
| MX2019003235A (es) | 2016-09-22 | 2019-07-08 | Regeneron Pharma | Metodos para tratar dermatitis atopica severa administrando un inhibidor de receptor de isoleucina-4. |
| JP6995844B2 (ja) | 2016-09-23 | 2022-02-04 | ジェネンテック， インコーポレイテッド | アトピー性皮膚炎を治療するためのｉｌ－１３アンタゴニストの使用 |
| TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| WO2019028367A1 (en) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES |
| MA46269B1 (fr) | 2017-08-18 | 2024-05-31 | Regeneron Pharma | Méthodes de traitement d'une dermatite atopique sévère par administration d'un inhibiteur des il-4r |
| US11034768B2 (en) | 2017-10-30 | 2021-06-15 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
| MX2020004469A (es) * | 2017-10-31 | 2020-09-07 | Oneness Biotech Co Ltd | Tratamiento de enfermedades alergicas mediadas por ige. |
| CN111566095B (zh) | 2017-11-03 | 2024-09-27 | 阿克拉瑞斯治疗股份有限公司 | 被取代的吡咯并吡啶jak抑制剂及其制造方法和使用方法 |
| WO2019150607A1 (ja) * | 2018-01-31 | 2019-08-08 | ＭｅｄｉＤｏｃ Ｓｅａｒｃｈ株式会社 | 広告提示方法、及び、広告提示システム |
| EP3793597A1 (en) * | 2018-05-13 | 2021-03-24 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r inhibitor |
| US11021482B2 (en) | 2018-08-10 | 2021-06-01 | Adaris Therapeutics, Inc. | Pyrrolopyrimidine ITK inhibitors |
| WO2020092015A1 (en) * | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| US11497718B2 (en) | 2018-11-13 | 2022-11-15 | Dermavant Sciences GmbH | Use of tapinarof for the treatment of atopic dermatitis |
| CN110746507B (zh) * | 2018-12-25 | 2020-06-26 | 江苏荃信生物医药有限公司 | 抗人白介素4受体α单克隆抗体及其应用 |
| JP2022526738A (ja) | 2019-03-21 | 2022-05-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | アレルギーを治療するためのｉｌ－４／ｉｌ－１３経路阻害剤と形質細胞除去の組み合わせ |
| MA55362A (fr) * | 2019-03-21 | 2022-01-26 | Regeneron Pharma | Formulations stabilisées contenant des anticorps anti-il-33 |
| CN112010977B (zh) * | 2019-05-29 | 2022-04-26 | 山东博安生物技术股份有限公司 | 抗白介素4受体(il-4r)的抗体及其应用 |
| BR112022000377A2 (pt) | 2019-08-05 | 2022-05-10 | Regeneron Pharma | Métodos para o tratamento de dermatite atópica por administração de antagonista de il-4r |
| CA3147068A1 (en) | 2019-08-05 | 2021-02-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist |
| US11748800B1 (en) * | 2019-09-11 | 2023-09-05 | Life Spectacular, Inc. | Generating skin care recommendations for a user based on skin product attributes and user location and demographic data |
| CN111825766B (zh) | 2019-10-31 | 2021-05-11 | 上海洛启生物医药技术有限公司 | 抗il-4r单域抗体及其应用 |
| JP2023504204A (ja) | 2019-12-09 | 2023-02-01 | サノフィ・バイオテクノロジー | デジタル的に識別されたｉｌ－４／ｉｌ－１３関連障害を治療する方法 |
| CN115427450A (zh) | 2020-03-27 | 2022-12-02 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗特应性皮炎的方法 |
| BR112022026237A2 (pt) | 2020-06-23 | 2023-01-17 | Crown Laboratories Inc | Formulações probióticas para a pele |
| KR20230123981A (ko) | 2020-12-23 | 2023-08-24 | 누맙 세러퓨틱스 아게 | Il-4r에 결합하는 항체 가변 도메인 |
| EP4019090A1 (en) | 2020-12-23 | 2022-06-29 | Numab Therapeutics AG | Antibody variable domains that bind il-4r |
| EP4019547A1 (en) | 2020-12-23 | 2022-06-29 | Numab Therapeutics AG | Multispecific antibodies having specificity for il-4r and il-31 |
| US11581084B2 (en) * | 2020-12-29 | 2023-02-14 | Kpn Innovations, Llc. | Systems and methods for generating an alimentary plan for managing skin disorders |
| AU2022224689A1 (en) * | 2021-02-18 | 2023-09-07 | Aclaris Therapeutics, Inc. | Topical formulations of a jak 1/3 inhibitor and methods of use thereof for treatment of atopic dermatitis and other skin conditions |
| CA3227014A1 (en) | 2021-08-23 | 2023-03-02 | Ashish Bansal | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| WO2023191665A1 (en) * | 2022-03-31 | 2023-10-05 | Milaboratory, Limited Liability Company | ANTIBODIES TO HUMAN IL-4Rα HAVING REDUCED IMMUNOGENICITY AND APPLICATION THEREOF |
| WO2024076731A1 (en) * | 2022-10-06 | 2024-04-11 | Regranion, Llc | Methods and compositions for treating hidradenitis suppurativa |
| WO2024097714A1 (en) | 2022-11-01 | 2024-05-10 | Regeneron Pharmaceuticals, Inc. | Methods for treating hand and foot dermatitis by administering an il-4r antagonist |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3315427B2 (ja) * | 1992-03-05 | 2002-08-19 | 大日本除蟲菊株式会社 | 皮膚炎治療剤 |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| EP1283851B1 (en) | 2000-05-26 | 2012-03-28 | Immunex Corporation | Use of il-4r antibodies and compositions thereof |
| JP4976636B2 (ja) * | 2000-07-26 | 2012-07-18 | 株式会社鳳凰堂 | 止痒性組成物及び創傷治癒促進組成物 |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JP5234445B2 (ja) * | 2004-10-05 | 2013-07-10 | 源一郎 杣 | 薬剤 |
| US7531637B2 (en) | 2005-05-06 | 2009-05-12 | Zymogenetics, Inc. | IL-31 monoclonal antibodies |
| EP2374818B1 (en) | 2006-06-02 | 2012-12-19 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human IL-6 receptor |
| US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| MX344294B (es) | 2010-10-06 | 2016-12-13 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r). |
| RU2453303C1 (ru) * | 2010-12-23 | 2012-06-20 | Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") | Фармацевтическая композиция для лечения атопического дерматита |
| PL2892927T3 (pl) * | 2012-09-07 | 2018-11-30 | Regeneron Pharmaceuticals, Inc. | Sposoby leczenia atopowego zapalenia skóry przez podawanie antagonisty IL-4R |
-
2013
- 2013-09-04 PL PL13765844T patent/PL2892927T3/pl unknown
- 2013-09-04 EP EP18161065.0A patent/EP3354663A1/en not_active Withdrawn
- 2013-09-04 RS RS20180802A patent/RS57520B1/sr unknown
- 2013-09-04 RU RU2015108073A patent/RU2666630C2/ru active
- 2013-09-04 NZ NZ748451A patent/NZ748451A/en unknown
- 2013-09-04 HU HUE21167811A patent/HUE066738T2/hu unknown
- 2013-09-04 RU RU2018131237A patent/RU2698907C2/ru active
- 2013-09-04 TR TR2018/08181T patent/TR201808181T4/tr unknown
- 2013-09-04 KR KR1020157008872A patent/KR102122708B1/ko active IP Right Grant
- 2013-09-04 CN CN202410387417.1A patent/CN118286430A/zh active Pending
- 2013-09-04 NZ NZ731864A patent/NZ731864A/en unknown
- 2013-09-04 EP EP24163612.5A patent/EP4374919A3/en active Pending
- 2013-09-04 DK DK13765844.9T patent/DK2892927T3/en active
- 2013-09-04 ES ES13765844.9T patent/ES2675779T3/es active Active
- 2013-09-04 PT PT211678115T patent/PT3889181T/pt unknown
- 2013-09-04 WO PCT/US2013/057898 patent/WO2014039461A1/en active Application Filing
- 2013-09-04 NZ NZ630178A patent/NZ630178A/en unknown
- 2013-09-04 CA CA2883936A patent/CA2883936C/en active Active
- 2013-09-04 AU AU2013312868A patent/AU2013312868B2/en active Active
- 2013-09-04 MX MX2015002873A patent/MX363193B/es unknown
- 2013-09-04 SG SG11201501011WA patent/SG11201501011WA/en unknown
- 2013-09-04 CN CN201380046623.6A patent/CN104995212A/zh active Pending
- 2013-09-04 EP EP13765844.9A patent/EP2892927B1/en not_active Revoked
- 2013-09-04 SG SG10201701798TA patent/SG10201701798TA/en unknown
- 2013-09-04 KR KR1020227011429A patent/KR102576903B1/ko active IP Right Grant
- 2013-09-04 HU HUE13765844A patent/HUE039387T2/hu unknown
- 2013-09-04 CN CN202410387527.8A patent/CN118286417A/zh active Pending
- 2013-09-04 JP JP2015531149A patent/JP6353838B2/ja active Active
- 2013-09-04 LT LTEP13765844.9T patent/LT2892927T/lt unknown
- 2013-09-04 US US14/017,333 patent/US20140072583A1/en not_active Abandoned
- 2013-09-04 EP EP21167811.5A patent/EP3889181B1/en active Active
- 2013-09-04 ES ES21167811T patent/ES2981062T3/es active Active
- 2013-09-04 BR BR112015005048A patent/BR112015005048A8/pt not_active Application Discontinuation
- 2013-09-04 SI SI201331084T patent/SI2892927T1/sl unknown
- 2013-09-04 KR KR1020217023487A patent/KR102385501B1/ko active IP Right Grant
- 2013-09-05 TW TW107106951A patent/TWI699212B/zh active
- 2013-09-05 TW TW112129255A patent/TWI852712B/zh active
- 2013-09-05 TW TW102131927A patent/TWI690328B/zh active
- 2013-09-05 TW TW111134046A patent/TWI814575B/zh active
- 2013-09-06 AR ARP130103184A patent/AR092475A1/es unknown
- 2013-09-06 UY UY0001035013A patent/UY35013A/es unknown
-
2015
- 2015-02-19 IL IL237328A patent/IL237328B/en unknown
- 2015-09-29 HK HK15109558.8A patent/HK1209132A1/xx not_active IP Right Cessation
-
2017
- 2017-05-31 US US15/610,267 patent/US20170333557A1/en not_active Abandoned
-
2018
- 2018-06-08 JP JP2018109925A patent/JP6637113B2/ja active Active
- 2018-06-18 AU AU2018204346A patent/AU2018204346B2/en active Active
- 2018-07-27 CY CY20181100782T patent/CY1121906T1/el unknown
- 2018-07-31 HR HRP20181227TT patent/HRP20181227T1/hr unknown
-
2019
- 2019-12-10 AU AU2019279946A patent/AU2019279946B2/en active Active
-
2021
- 2021-09-23 AU AU2021236538A patent/AU2021236538B2/en active Active
-
2022
- 2022-09-23 US US17/951,987 patent/US20230058395A1/en active Pending
-
2023
- 2023-03-29 JP JP2023052545A patent/JP2023082091A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018131237A (ru) | Способы лечения атопического дерматита с помощью антагониста il-4r | |
| RU2016136364A (ru) | Способы лечения или предупреждения астмы посредством введения антагониста il-4r | |
| HRP20231156T1 (hr) | Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka | |
| RU2014148502A (ru) | Человеческие антитела к fel d1 и способы их применения | |
| JP2019523295A5 (ru) | ||
| JP2013542194A5 (ru) | ||
| JP2017507139A5 (ru) | ||
| RU2017102926A (ru) | Композиции для лечения рака с применением антагонистов, связывающихся с компонентом сигнального пути pd-1, и ингибиторов мек | |
| HRP20100014T1 (hr) | Uporaba il-23 i il-17 antagonista u liječenju autoimune očne upalne bolesti | |
| RU2013155906A (ru) | Антитела анти-angptl3 и их применение | |
| IL273678B1 (en) | Methods for treating allergy and improving allergen-specific immunotherapy by administering an IL-4R inhibitor | |
| SI2766039T1 (en) | Ingredients for the treatment of rheumatoid arthritis and procedures for their use | |
| RU2015144666A (ru) | Терапия для лечения рака, включающая антитела против клаудина 18.2 | |
| RU2015112576A (ru) | Комбинированная терапия с использованием антитела против cd20 типа ii и селективного ингибитора bcl-2 | |
| AU2011328393A1 (en) | Prevention of adverse effects caused by CD3 specific binding domains | |
| JP2018512435A5 (ru) | ||
| JP2015523962A5 (ru) | ||
| WO2005044854A3 (en) | Antagonist anti-cd40 monoclonal antibodies and methods for their use | |
| RU2019111921A (ru) | Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r | |
| FI3778641T3 (fi) | Bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat CD3:a ja CD20:tä, ja niiden käyttöjä | |
| RU2016130056A (ru) | Способы лечения кожной инфекции путем введения антагониста il-4r | |
| JP2020502261A5 (ru) | ||
| JP2020500152A5 (ru) | ||
| RU2010132178A (ru) | Агенты, уменьшающие количество в-клеток, такие как антитела против cd20 или их фрагменты, для лечения синдрома хронической усталости | |
| JP2019512472A5 (ru) |